"Cet établissement gériatrique, a pour objectif de développer des prises en charges adaptées aux pathologies spécifiques du sujet âgé et des soins de recours spécialisés, en lien permanent avec le médecin traitant du patient. Au-delà des prises en charge de pointe qu’il propose en matière de médecine du vieillissement, l’hôpital gériatrique des Charpennes est aujourd’hui particulièrement renommé dans les pathologies de la mémoire, maladies d’Alzheimer et apparentées. Il propose de nombreuses consultations spécialisées complétées par des séjours en hôpital de jour pour réaliser les compléments diagnostiques nécessaires. Cet établissement fait partie de l’Institut du Vieillissement des Hospices Civils de Lyon."

During the past decade, Hopital des Charpennes conducted 21 clinical trials. In the 10-year time frame, 21 clinical trials started and 8 clinical trials were completed, i.e. on average, 38.1% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 8 clinical trials were completed. i.e. 114.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hopital des Charpennes" #1 sponsor was "Hospices Civils de Lyon" with 8 trials, followed by "Hoffmann-La Roche" with 4 trials sponsored, "Biogen" with 3 trials sponsored, "TauRx Therapeutics Ltd" with 3 trials sponsored and "AstraZeneca" with 3 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hopital des Charpennes" #1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator, "Caisse Nationale de Solidarité pour l'Autonomie" with 1 trials as a collaborator, "Direction Générale de la Santé, France" with 1 trials as a collaborator, "Institut National de la Santé Et de la Recherche Médicale, France" with 1 trials as a collaborator and "Lili smart" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Hopital des Charpennes" are "Alzheimer's Disease" (11 trials), "Alzheimer Disease" (6 trials), "Alzheimer´s Disease" (1 trials), "Atrial Fibrillation" (1 trials) and "Behavioral Disorder" (1 trials). Many other conditions were trialed in "Hopital des Charpennes" in a lesser frequency.

Most popular intervention types in "Hopital des Charpennes" are "Drug" (15 trials), "Other" (4 trials), "Behavioral" (3 trials), "Biological" (1 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "Gantenerumab" (2 trials), "Lanabecestat" (2 trials), "Semorinemab" (2 trials) and "[18F]GTP1" (2 trials). Other intervention names were less common.

The vast majority of trials in "Hopital des Charpennes" are 24 trials for "All" genders.

Currently, there are NaN active trials in "Hopital des Charpennes". undefined are not yet recruiting, 4 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Hopital des Charpennes, 1 suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Hopital des Charpennes, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 6 trials that are defined as “Not Applicable".